Combination therapy/prophylaxis with interferon and ribavirin for recurrent hepatitis C after liver transplantation: long-term effects on graft function and morphology.
Kornberg
A
A
Department of General and Visceral Surgery, Friedrich-Schiller-University, Jena, Germany. Arno.Kornberg@med.uni-jena.de
Hommann
M
M
Tannapfel
A
A
Grube
T
T
Schotte
U
U
Scheele
J
J
D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology* / Q000601:surgery; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase